WB, IP, IF-IC, FC-FP
H
Endogenous
45-70
Rabbit IgG
#P36941
4055
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Immunofluorescence (Immunocytochemistry) | 1:200 - 1:800 |
| Flow Cytometry (Fixed/Permeabilized) | 1:400 - 1:600 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg428 of human LTβR protein.
Background
Lymphotoxin β receptor (LTβR), also known as tumor necrosis factor receptor superfamily member 3 (TNFRSF3) and tumor necrosis factor receptor type III (TNF-RIII), is a type I membrane receptor expressed by stromal cells, including endothelial, mesenchymal, and epithelial cells, and by myeloid cells, such as dendritic cells and macrophages (1-4). When lymphotoxin α (LTα) is co-expressed with lymphotoxin β (LTβ) that possesses a transmembrane domain, it forms a cell surface-bound heterotrimer (LTα1β2) that exclusively binds to LTβR (5,6). The LTα1β2/LTβR pathway is required for the normal development of lymph nodes and Peyer’s patches (7,8). Disruption of the LTα1β2/LTβR pathway results in impaired protection from viral and bacterial infections (9,10). LTβR is also a receptor for LIGHT/TNFSF14 (11,12). LTβR signaling through LIGHT/TNFSF14 regulates self-renewal and differentiation of hematopoietic and leukemic stem cells (13). In cancer cells, LTβR signaling via TRAF molecules promotes apoptosis (14-16). Agonistic antibodies to LTβR trigger cancer cell death and suppress tumor growth in vivo (17).
- Murphy, M. et al. (1998) Cell Death Differ 5, 497-505.
- Browning, J.L. and French, L.E. (2002) J Immunol 168, 5079-87.
- Browning, J.L. et al. (1997) J Immunol 159, 3288-98.
- Kabashima, K. et al. (2005) Immunity 22, 439-50.
- Androlewicz, M.J. et al. (1992) J Biol Chem 267, 2542-7.
- Browning, J.L. et al. (1993) Cell 72, 847-56.
- De Togni, P. et al. (1994) Science 264, 703-7.
- Fütterer, A. et al. (1998) Immunity 9, 59-70.
- Ehlers, S. et al. (2003) J Immunol 170, 5210-8.
- Wege, A.K. et al. (2014) Innate Immun 20, 461-70.
- Maeda, T. et al. (2018) J Immunol 201, 202-214.
- Schneider, K. et al. (2004) Immunol Rev 202, 49-66.
- Höpner, S.S. et al. (2021) Nat Commun 12, 1065.
- Browning, J.L. et al. (1996) J Exp Med 183, 867-78.
- Force, W.R. et al. (1997) J Biol Chem 272, 30835-40.
- Rooney, I.A. et al. (2000) J Biol Chem 275, 14307-15.
- Lukashev, M. et al. (2006) Cancer Res 66, 9617-24.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation IF-IC: Immunofluorescence (Immunocytochemistry) FC-FP: Flow Cytometry (Fixed/Permeabilized)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.